MCID: SBS003
MIFTS: 51

Substance Abuse

Categories: Mental diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse 11 28 14 75
Substance-Related Disorders 43 71
Substance Abuse Problem 71

Classifications:



External Ids:

Disease Ontology 11 DOID:302
MeSH 43 D019966
NCIt 49 C16522
SNOMED-CT 68 26416006
UMLS 71 C0013146 C0236969 C0740858

Summaries for Substance Abuse

Disease Ontology: 11 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary: Substance Abuse, also known as substance-related disorders, is related to cannabis abuse and antisocial personality disorder, and has symptoms including symptoms An important gene associated with Substance Abuse is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are Tamoxifen metabolism and Neurotransmitter clearance. The drugs Olanzapine and Valproic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and cingulate cortex, and related phenotypes are nervous system and homeostasis/metabolism

Wikipedia: 75 Substance abuse, also known as drug abuse, is the use of a drug in amounts or by methods which are... more...

Related Diseases for Substance Abuse

Diseases in the Substance Abuse family:

T-Substance Anomaly

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 525)
# Related Disease Score Top Affiliating Genes
1 cannabis abuse 32.5 SLC6A4 PRODH DRD2 COMT BDNF
2 antisocial personality disorder 32.5 SLC6A4 SLC6A3 PRL GABRA2 DRD2 COMT
3 opioid abuse 32.5 OPRM1 DRD2 CYP2D6 CCR6 CCR5
4 eating disorder 32.4 SLC6A4 SLC6A3 OPRM1 H2AC18 DRD2 COMT
5 bipolar disorder 32.4 SLC6A4 SLC6A3 PRODH PRL OPRM1 GABRA2
6 alcohol use disorder 32.3 TF SLC6A4 SLC6A3 SERPINA3 PRODH OPRM1
7 cocaine abuse 32.3 SLC6A4 SLC6A3 OPRM1 H2AC18 DRD3 DRD2
8 schizoaffective disorder 32.3 SLC6A4 SERPINA3 PRODH PRL DRD3 DRD2
9 amphetamine abuse 32.2 SLC6A4 SLC6A3
10 schizophrenia 32.1 SLC6A4 SLC6A3 SERPINA3 PRODH PRL OPRM1
11 post-traumatic stress disorder 32.0 SLC6A4 SLC6A3 H2AC18 DRD2 COMT BDNF
12 personality disorder 31.9 SLC6A4 SLC6A3 PRL DRD3 DRD2 COMT
13 polysubstance abuse 31.9 DRD3 DRD2 COMT
14 alcohol dependence 31.8 TF SLC6A4 SLC6A3 SERPINA3 OPRM1 H2AC18
15 conduct disorder 31.7 SLC6A4 SLC6A3 GABRA2 DRD2 COMT
16 disease of mental health 31.7 SLC6A4 SLC6A3 SERPINA3 PRODH OPRM1 H2AC18
17 drug dependence 31.7 SLC6A4 SLC6A3 OPRM1 GABRA2 DRD3 DRD2
18 substance dependence 31.6 SLC6A4 SLC6A3 SERPINA3 OPRM1 H2AC18 GABRA2
19 chronic pain 31.6 OPRM1 COMT BDNF
20 opiate dependence 31.5 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 COMT
21 major depressive disorder 31.5 SLC6A4 SLC6A3 PRL OPRM1 DRD3 DRD2
22 anxiety 31.5 SLC6A4 SLC6A3 PRODH PRL OPRM1 GABRA2
23 tobacco addiction 31.5 SLC6A4 SLC6A3 OPRM1 H2AC18 GABRA2 DRD3
24 attention deficit-hyperactivity disorder 31.5 SLC6A4 SLC6A3 SERPINA3 PRODH OPRM1 H2AC18
25 psychotic disorder 31.5 SLC6A4 SLC6A3 SERPINA3 PRODH PRL OPRM1
26 bulimia nervosa 31.4 SLC6A4 SLC6A3 DRD2 COMT BDNF
27 borderline personality disorder 31.4 SLC6A4 SLC6A3 PRL DRD2 COMT BDNF
28 mood disorder 31.4 SLC6A4 SLC6A3 SERPINA3 PRODH H2AC18 DRD3
29 panic disorder 31.3 SLC6A4 SLC6A3 PRL DRD3 DRD2 COMT
30 cocaine dependence 31.3 SLC6A4 SLC6A3 PRL OPRM1 GABRA2 DRD3
31 anorexia nervosa 31.2 SLC6A4 PRL DRD2 COMT BDNF
32 pathological gambling 31.2 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 COMT
33 learning disability 31.1 PRODH H2AC18 COMT BDNF
34 viral infectious disease 31.1 SERPINA3 H2AC18 CCR6 CCR5
35 adjustment disorder 31.1 SLC6A4 CYP2D6 BDNF
36 generalized anxiety disorder 31.1 SLC6A4 PRODH H2AC18 DRD2 CYP2D6 COMT
37 cannabis dependence 31.0 GABRA2 DRD2 COMT
38 sleep disorder 31.0 SLC6A4 SLC6A3 H2AC18 COMT BDNF
39 neonatal abstinence syndrome 30.9 OPRM1 CYP2D6 COMT
40 dystonia 30.9 SLC6A3 PRL DRD3 DRD2 CYP2D6 COMT
41 gilles de la tourette syndrome 30.9 SLC6A4 SLC6A3 DRD3 DRD2 COMT BDNF
42 dysthymic disorder 30.9 SLC6A4 SLC6A3 PRODH CYP2D6 COMT BDNF
43 bipolar i disorder 30.9 SLC6A4 PRODH PRL DRD2 CYP2D6 COMT
44 tardive dyskinesia 30.9 DRD2 CYP2D6 COMT
45 social phobia 30.9 SLC6A4 SLC6A3 SERPINA3 PRODH PRL DRD2
46 neurotic disorder 30.9 SLC6A4 COMT BDNF
47 sexual health disorder 30.9 SLC6A4 PRL H2AC18
48 obsessive-compulsive disorder 30.9 SLC6A4 SLC6A3 PRL DRD3 DRD2 CYP2D6
49 human immunodeficiency virus infectious disease 30.9 SERPINA3 H2AC18 CCR6 CCR5
50 withdrawal disorder 30.9 SLC6A4 SLC6A3 OPRM1 DRD2 CYP2D6 BDNF

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to Substance Abuse

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:


symptoms

MGI Mouse Phenotypes related to Substance Abuse:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.13 ABCB7 BDNF CCR5 CCR6 COMT DRD2
2 homeostasis/metabolism MP:0005376 10.09 ABCB7 BCHE BDNF CCR5 CCR6 COMT
3 behavior/neurological MP:0005386 9.8 BDNF CCR5 COMT DRD2 DRD3 GABRA2
4 integument MP:0010771 9.32 BDNF CYP2D6 DRD2 GABRA2 OPRM1 PRL

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 380)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Olanzapine Approved, Investigational Phase 4 132539-06-1 135398745 4585
2
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
3
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
4
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
5
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
6
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
7
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
8
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
9
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
10
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
11
Desipramine Approved, Investigational Phase 4 50-47-5 2995
12
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
13
Amantadine Approved Phase 4 768-94-5 2130
14
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 77335690 67683363
15
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
16
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
17
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
18
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
19
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
20
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
21
Vancomycin Approved Phase 4 1404-90-6 14969
22
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
23
Ceftriaxone Approved Phase 4 73384-59-5 5479530
24
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3 72562361
25
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
26
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
27
Ofloxacin Approved Phase 4 82419-36-1 4583
28
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
29
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
30
Rifampicin Approved Phase 4 13292-46-1 135512673 5381226 135900090
31
Dicloxacillin Approved, Investigational, Vet_approved Phase 4 3116-76-5 18381
32
Oxacillin Approved, Investigational Phase 4 66-79-5 6196
33
Oritavancin Approved, Investigational Phase 4 171099-57-3 16136912
34
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
35
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
36
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
37
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
38
Diamorphine Approved, Illicit, Investigational Phase 4 561-27-3 5462328
39
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
40
Clozapine Approved Phase 4 5786-21-0 2818 135398737
41
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
42
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
43
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
44
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
45 Anti-Infective Agents, Local Phase 4
46 Liver Extracts Phase 4
47 interferons Phase 4
48 Respiratory System Agents Phase 4
49 Serotonin 5-HT1 Receptor Agonists Phase 4
50 Antimetabolites Phase 4

Interventional clinical trials:

(show top 50) (show all 1677)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse, Part 1 Unknown status NCT00000346 Phase 4
2 Intravenous Lidocaine for Perioperative and Postoperative Analgesia Unknown status NCT03921567 Phase 4 Lidocaine Hydrochloride;Lidocaine Hydrochloride and Ketamine;Placebo
3 Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder Unknown status NCT03857581 Phase 4 Clozapine;Olanzapine
4 Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents Unknown status NCT00536419 Phase 4 Methylphenidate
5 Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder Unknown status NCT02477280 Phase 4 Methylphenidate;Placebo
6 A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users Unknown status NCT02192931 Phase 4 Creatine monohydrate
7 Translating Depression Guidelines Into Substance Abuse Treatment Completed NCT00137306 Phase 4
8 A Double-blind Placebo Controlled Trial of Pregnenolone for Depression in Patients With Bipolar Disorders or Recurrent Major Depressive Disorder and a History of Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
9 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
10 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
11 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
12 A Prospective Cohort Study Comparing the Effectiveness of Zepatier for the Treatment of Hepatitis C in an Academic Center Population to People Who Inject Drugs (PWIDs) in a Safety Net Clinic Setting Engaged in Either a Medication Assisted Therapy (MAT) or Syringe Exchange Program Completed NCT03093415 Phase 4 elbasvir-grazoprevir (50 mg/100 mg)
13 People Who Inject Drugs; Longitudinal Staphylococcus Aureus Colonization Pattern and the Impact on Infection Frequency by Regular Showers With Chlorhexidine Completed NCT03940729 Phase 4 Chlorhexidine Topical
14 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
15 Randomized Clinical Trial Comparing a Medication, i.e., Sustained-Release Bupropion (Zyban®) With an Ultrashort (1 1/2 d) Manual-Based Psychotherapeutic Intervention, Psychodynamic Model Training® Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
16 Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia Completed NCT00156715 Phase 4 Quetiapine
17 Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST) Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
18 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
19 Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder Completed NCT00203528 Phase 4 divalproex sodium ER;risperidone
20 Creatine as a Treatment Option for Depression in Methamphetamine Using Females Completed NCT01514630 Phase 4 Creatine monohydrate
21 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4 Apo-Oxycodone CR®;OxyNEO®;Placebo
22 Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO) Completed NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
23 Drug Contextual Conditioning With in Humans: Causes and Consequences Completed NCT03075501 Phase 4 Stimulant or sedative;Placebo
24 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
25 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
26 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4 Varenicline;Placebo
27 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
28 Brain Changes in Stimulant Dependent Subjects Completed NCT00000343 Phase 4
29 Methamphetamine Abuse Pharmacology in Patients With AIDS Completed NCT00000321 Phase 4 Desipramine
30 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
31 Methylphenidate Raclopride PET Test Completed NCT00015301 Phase 4 Methylphenidate
32 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
33 Modeling Impaired Judgement in Cocaine Abusers Completed NCT00015236 Phase 4
34 Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD) Completed NCT00218322 Phase 4 Atomoxetine hydrochloride;Placebo
35 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
36 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
37 Multimodal Treatment Study of Children With ADHD Completed NCT00000388 Phase 4 Anti-ADHD medication
38 Smoking Cessation Treatment for Methadone Maintenance Patients Completed NCT01027754 Phase 4 Varenicline;Placebo
39 VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
40 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
41 Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
42 Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use Completed NCT03842436 Phase 4 Truvada
43 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
44 Feasibility of Emergency Department Initiated Extended-Release Naltrexone and Case Management Services for the Treatment of Alcohol Use Disorder Completed NCT04094584 Phase 4 Vivitrol (Extended Release Naltrexone)
45 Management of Hepatitis C Virus (HCV) Infection in Pregnant Women With Opioid Use Disorder (OUD): the Potential of an Integrated Medical Home Model: Phase IV Trial of Sofosbuvir/Velpatasvir (SOF/VEL) in Postpartum Women With Chronic HCV Completed NCT03057847 Phase 4 Sofosbuvir/Velpatasvir
46 Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers Completed NCT00685620 Phase 4
47 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
48 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
49 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
50 A Phase 4, Single-Arm Study of the Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Patients With Active Illicit Substance Use Completed NCT03998176 Phase 4 Bictegravir/emtricitabine/tenofovir alafenamide

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Desipramine
Desipramine Hydrochloride
Doxapram
Doxapram Hydrochloride

Cochrane evidence based reviews: substance-related disorders

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

# Genetic test Affiliating Genes
1 Substance Abuse 28

Anatomical Context for Substance Abuse

Organs/tissues related to Substance Abuse:

MalaCards : Brain, Prefrontal Cortex, Cingulate Cortex, Cortex, Eye, Heart, Spinal Cord

Publications for Substance Abuse

Articles related to Substance Abuse:

(show top 50) (show all 25767)
# Title Authors PMID Year
1
Sleep-mediated regulation of reward circuits: implications in substance use disorders. 62
35710601 2023
2
A Pragmatic Clinical Approach to Substance Abuse Prevention. 62
36410897 2023
3
Adaptation of the Devaluation-Discrimination Scale Into Turkish: A Comprehensive Psychometric Analysis. 62
34459254 2023
4
Depression and Suicidal Behavior in Adolescents. 62
36402497 2023
5
Primary mental healthcare for adults with mild intellectual disabilities: a Dutch database study. 62
36412308 2022
6
Can cannabis kill? Characteristics of deaths following cannabis use in England (1998-2020). 62
35946604 2022
7
Childhood stress and midlife depression in women: the influence of diet quality. 62
34844523 2022
8
Temporal trends and disparities in gastroenterology care use before, during, and after COVID-19 lockdown. 62
36038149 2022
9
Trends in buprenorphine-waivered providers in Medicaid expansion and non-expansion states by their public listing status. 62
35442126 2022
10
Mental health symptom changes in pregnant individuals across the COVID-19 pandemic: a prospective longitudinal study. 62
36463120 2022
11
Clustering of homicide with other adverse health outcomes in the Netherlands. 62
36164507 2022
12
Prevalence and risk factors of non-adherence to antipsychotic medications in Saudi Arabia. 62
36458442 2022
13
Effect of Amoxicillin/Clavulanic acid in attenuating Pregabalin-induced Condition Place Preference. 62
36470419 2022
14
Predicting Young Adult Tobacco, Drug and Alcohol Use Among Participants in the CAMP Trial. 62
35013874 2022
15
Childhood Experiences of Companion Animal Abuse and its Co-Occurrence with Domestic Abuse: Evidence from a National Youth Survey in Norway. 62
35156447 2022
16
Differences Between Sexual and Nonsexual Homicides of Women in the United States: Findings From the National Violent Death Reporting System. 62
34990564 2022
17
Gender Differences Between Domestic Violent Men and Women: Criminogenic Risk Factors and Their Association With Treatment Dropout. 62
34965769 2022
18
[Illicit Drug Exposures Reported to the Poisons Information Centre Erfurt (2011 to 2020)]. 62
34598281 2022
19
Getting to the Sandbar: Understanding the Emotional Phases of COVID-19 Among College and University Students. 62
34225513 2022
20
Tramadol misuse in treatment-seeking adolescents and young adults with problematic substance use - Prediction of treatment retention. 62
35875347 2022
21
Changes in the Risk of Sexual Reoffending: The Role and Relevance of Perceived Self-Efficacy and Adult Attachment Styles in Correctional Treatment. 62
34724856 2022
22
The prevalence of substance abuse and associated factors among male prisoners in Karachi jails, Pakistan. 62
36212581 2022
23
Analysis of hospital costs by morbidity group for patients with severe mental illness. 62
35318876 2022
24
Racial/ethnic residential segregation and the availability of opioid and substance use treatment facilities in US counties, 2009-2019. 62
36457346 2022
25
Signs and symptoms of COVID-19 in patients with multiple sclerosis. 62
36086905 2022
26
Social Disparities among Sudden Death victims with HIV. 62
35672553 2022
27
Sexually transmitted infections among patients attending a sexual assault centre: a cohort study from Oslo, Norway. 62
36456026 2022
28
Risk factors for comorbid epilepsy in patients with psychogenic non-epileptic seizures. Dataset of a large cohort study. 62
36160062 2022
29
Electrophysiological and behavioral correlates of cannabis use disorder. 62
35698004 2022
30
Developing a National Trauma Research Action Plan: Results from the long-term outcomes research gap Delphi survey. 62
35972140 2022
31
Association of Adverse Childhood Experiences and Social Isolation With Later-Life Cognitive Function Among Adults in China. 62
36367722 2022
32
Impacts of the New York State COVID-19 Disaster Emergency Orders on prescription dispensing for opioids and medication for opioid use disorder. 62
36398540 2022
33
Substance use, mental health and dual disorders on pregnancy: Results of prevalence and treatment rates in a developed country. 62
33768264 2022
34
Psychological Reactions to Different Types of Gender-Based Violence in Women Survivors of Violence in the Context of a Developing Country. 62
34625007 2022
35
Case report of a phencyclidine false positive due to lamotrigine use with confirmatory testing. 62
35961834 2022
36
Parental alcohol and drug abuse and offspring mortality by age 10: a population-based register study. 62
36172920 2022
37
Cognitive and Neuropsychiatric Impairment in Dystonia. 62
36201146 2022
38
Alcohol, nicotine, and COVID-19: A retrospective study of health outcomes in central Pennsylvania. 62
36442695 2022
39
Sex, Race, Insurance, and Pain: Do Patient Sociodemographics Influence Postoperative Opioid Prescriptions Among Hand Surgeons? 62
33682465 2022
40
Epidemiological Trend of Esophageal Cancer at a Tertiary Cancer Center in Mumbai, India, Over the Past 15 Years. 62
36418768 2022
41
Association between attention deficit hyperactivity disorder and outcomes after metabolic and bariatric surgery: a nationwide propensity-matched cohort study. 62
36443212 2022
42
The Role of Gender in the Association between Mental Health and Potentially Preventable Hospitalizations: A Single-Center Retrospective Observational Study. 62
36429414 2022
43
Predictors of illicit substance abuse/dependence during young adulthood: A machine learning approach. 62
36470198 2022
44
Are trauma surgical societies adequately addressing mental health after injury? 62
35981920 2022
45
Characterizing OPRM1 DNA methylation in prescription opioid users with chronic musculoskeletal pain. 62
36447952 2022
46
Transient global amnesia: Uncommon diagnosis of exclusion. 62
36439382 2022
47
Associations between Homelessness and Alzheimer's Disease and Related Dementia: A Systematic Review. 62
35750476 2022
48
Psychological and physical wellbeing in adults who grew up with a mentally ill parent: A systematic mixed-studies review. 62
36471514 2022
49
Movement if Life-Optimizing Patient Access to Total Joint Arthroplasty: Alcohol and Substance Abuse Disparities. 62
35442926 2022
50
Impact of Opioid Epidemic on Infective Endocarditis Outcomes in the United States: From the National Readmission Database. 62
36085056 2022

Variations for Substance Abuse

Expression for Substance Abuse

Search GEO for disease gene expression data for Substance Abuse.

Pathways for Substance Abuse

GO Terms for Substance Abuse

Cellular components related to Substance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005887 10.23 CCR5 CCR6 DRD2 DRD3 GABRA2 OPRM1
2 plasma membrane GO:0005886 10.23 CCR5 CCR6 DRD2 DRD3 GABRA2 OPRM1
3 axon GO:0030424 10.15 SLC6A3 OPRM1 GABRA2 DRD2 COMT BDNF
4 presynaptic membrane GO:0042734 9.72 SLC6A4 SLC6A3 OPRM1 DRD2
5 postsynaptic membrane GO:0045211 9.65 SLC6A4 SLC6A3 OPRM1 GABRA2 DRD2
6 obsolete integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 SLC6A3 OPRM1 DRD2
7 obsolete integral component of postsynaptic membrane GO:0099055 8.92 SLC6A4 SLC6A3 OPRM1 DRD2

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 response to xenobiotic stimulus GO:0009410 10.11 SLC6A4 SLC6A3 DRD3 DRD2 BCHE
2 neurotransmitter transport GO:0006836 10.02 SLC6A4 SLC6A3 GABRA2
3 hyaloid vascular plexus regression GO:1990384 9.86 SLC6A3 DRD2
4 dopamine uptake involved in synaptic transmission GO:0051583 9.84 SLC6A3 DRD2
5 monoterpenoid metabolic process GO:0016098 9.83 CYP2D6 CYP2C19
6 response to ethanol GO:0045471 9.83 DRD2 DRD3 OPRM1 SLC6A3
7 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.81 DRD2 DRD3
8 regulation of potassium ion transport GO:0043266 9.8 DRD2 DRD3
9 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.78 DRD2 DRD3
10 acid secretion GO:0046717 9.71 DRD3 DRD2
11 response to histamine GO:0034776 9.67 DRD3 DRD2
12 response to morphine GO:0043278 9.65 OPRM1 DRD3 DRD2
13 dopamine metabolic process GO:0042417 9.63 DRD3 DRD2 COMT
14 regulation of locomotion involved in locomotory behavior GO:0090325 9.62 DRD3 DRD2
15 prepulse inhibition GO:0060134 9.43 SLC6A3 DRD3 DRD2
16 response to cocaine GO:0042220 9.23 SLC6A3 OPRM1 DRD3 DRD2

Molecular functions related to Substance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dopamine binding GO:0035240 9.46 SLC6A3 DRD2
2 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD3 DRD2
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.92 DRD3 DRD2

Sources for Substance Abuse

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....